CAPR - Company ID 0001133869
The table below shows CAPRICOR THERAPEUTICS, INC.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$29.25M | -$6.43M | -$1.27M | $4.21M | $24.05M | -$3.33M |
| Capital expenditure | $5.12M | $896.01K | $608.59K | $347.69K | $567.62K | $36.91K |
| Investing cash flow | -$154.64M | $23.89M | -$9.50M | -$3.21M | -$625.36K | -$36.91K |
| Dividends paid | - | - | - |
CAPRICOR THERAPEUTICS, INC. reported operating cash flow of -$69.81M for fiscal year 2025. That is down 74.5% from -$40.00M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$14.45M (FY 2016) to -$69.81M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $1.47M | $50.35K | $2.29M | $3.90K | $27.46K | $12.58M |